NRAS and melanoma: Transformation of melanoma cells associated with somatic mutations in the proto-oncogenes, B-Raf (BRAF) and Neuroblastoma RAS (NRAS), allowing tyrosine kinase inhibitors (e.g., vemurafenib, dabrafenib, and trametinib) to be successfully applied as melanoma treatments 2, 3.